Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $33.59 USD
Change Today +0.34 / 1.02%
Volume 16.5M
PFE On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 2:33 PM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE) Snapshot

Open
$33.34
Previous Close
$33.25
Day High
$33.67
Day Low
$33.15
52 Week High
04/13/15 - $35.53
52 Week Low
10/16/14 - $27.51
Market Cap
206.4B
Average Volume 10 Days
25.0M
EPS TTM
$1.81
Shares Outstanding
6.2B
EX-Date
08/5/15
P/E TM
18.6x
Dividend
$1.12
Dividend Yield
3.21%
Current Stock Chart for PFIZER INC (PFE)

pfizer inc (PFE) Details

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has collaboration with BIND Therapeutics, Inc. to develop and commercialize multiple Accurins. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

78,300 Employees
Last Reported Date: 02/27/15
Founded in 1849

pfizer inc (PFE) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.3M
President of Worldwide Research & Development
Total Annual Compensation: $1.2M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $1.2M
Group President of Global Established Pharma ...
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2014.

pfizer inc (PFE) Key Developments

Portola Pharmaceuticals, Bristol-Myers Squibb Company and Pfizer Inc. Announce Positive Data from Phase III Bleeding Study

Portola Pharmaceuticals, Bristol-Myers Squibb Company (BMS) and Pfizer Inc. announced data from the second part of the Phase III Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors - Apixaban or ANNEXA-A, study, which demonstrated that andexanet alfa has sustained reversal of anticoagulation activity of factor Xa inhibitor, Eliquis. This second part of the study achieved all primary and pre-specified secondary endpoints with high statistical significance. Andexanet alfa produced rapid reversal of the anticoagulant effect of Eliquis, as measured by anti-Factor Xa activity, which was sustained for the duration of the infusion. Andexanet alfa significantly reduced the level of free unbound Eliquis in the plasma and restored thrombin generation to normal. Andexanet alfa was well tolerated, with no serious adverse events, thrombotic events, or antibodies to Factor X or Xa reported. Mild infusion reactions were reported in six subjects: four in the andexanet arm and two in the placebo arm. No subjects discontinued the study due to an adverse event. Portola plans to submit data from the ANNEXA-A (apixaban) and ANNEXA-R (rivaroxaban) studies, and initial data from a Phase IV study, as part of its Biologics License Application (BLA) to the FDA under an Accelerated Approval pathway by the end of 2015. The randomized, double-blind, placebo-controlled Phase III ANNEXA-A study evaluated the safety and efficacy of andexanet alfa in reversing apixaban-induced anticoagulation in older healthy volunteers ages 50-75 years. Efficacy was evaluated using biomarker endpoints, with anti-Factor Xa levels as the primary endpoint. Secondary endpoints included plasma levels of free unbound apixaban and endogenous thrombin potential (ETP), a measure of thrombin generation. In ANNEXA-A Part 1, 33 healthy volunteers were given apixaban 5 mg twice daily for four days and then randomized in a 3:1 ratio to andexanet alfa administered as a 400 mg IV bolus (n=24) or to placebo (n=9). In the second part of the study, 31 healthy volunteers were given apixaban 5 mg twice daily for four days and then randomized in a 3:1 ratio to andexanet alfa administered as a 400 mg IV bolus followed by a continuous infusion of 4 mg/min for 120 minutes (n=23) or to placebo (n=8). Results showed that, following the administration of a bolus of andexanet alfa, the anticoagulant activity of apixaban, as measured by anti-Factor Xa activity, was reversed by 93.5% (p<0.0001). Following completion of the two-hour continuous infusion of andexanet alfa, the anticoagulant activity of apixaban remained significantly reversed, by 92.7% (p<0.0001). These two endpoints demonstrate that andexanet alfa infusion was able to keep anti-Factor Xa levels flat from the end of the bolus (93.5%) to the end of the two-hour infusion (92.7%). Additional secondary endpoints showed: reversal of at least 80% of anti-Factor Xa activity occurred in all 23 subjects who received andexanet alfa (p<0.0001); plasma levels of free unbound apixaban were significantly reduced with andexanet alfa (p=0.0002); thrombin generation at peak (end of infusion) was restored to the normal range in 23 out of 23 (100 percent) andexanet alfa recipients; and thrombin generation above the lower limit of normal occurred in all 23 subjects who received andexanet alfa (p<0.0001). No serious adverse events, thrombotic events, or antibodies to Factor X or Xa were reported following andexanet alfa administration. Mild infusion reactions were reported in six subjects. No subjects discontinued the study due to an adverse event.

Pfizer Announces FDA Acceptance for Review of New Drug Application for Once-Daily Formulation of Xeljanz (Tofacitinib Citrate) Modified Release Tablets

Pfizer Inc. announced that the United States Food and Drug Administration (FDA) accepted for review Pfizer’s new drug application (NDA) for XELJANZ (tofacitinib citrate) 11 mg once daily modified release tablets for the treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX). The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in February 2016 for the NDA. The NDA for XELJANZ 11 mg once daily modified release is based on data from a clinical pharmacology program designed to demonstrate equivalence in key pharmacokinetic parameters to XELJANZ 5 mg twice daily.

Pfizer Inc. Appoints Joseph J. Echevarria as Director

Pfizer Inc. announced the election of Joseph J. Echevarria to its Board of Directors, effective immediately. Mr. Echevarria also was appointed to the Audit, Regulatory and Compliance and Science and Technology Committees of Pfizer’s Board. Mr. Echevarria retired as Chief Executive Officer (CEO) of Deloitte LLP, in August 2014. He had been with the firm for 36 years and served in various leadership roles, including Deputy Managing Partner, Southeast Region Audit Managing Partner, U.S. Managing Partner and Chief Operating Officer. He was appointed CEO in 2011. Mr. Echevarria serves as a Director of The Bank of New York Mellon Corporation. He is a member of the President’s Export Council and the Presidential Commission on Election Administration and also serves as Chair of President Obama’s My Brother’s Keeper Alliance. He serves on the Board of Trustees of the University of Miami.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:US $33.59 USD +0.335

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $114.43 USD -1.23
Merck & Co Inc $57.64 USD +0.085
Nestle SA SFr.68.60 CHF -0.20
Roche Holding AG SFr.260.20 CHF -5.20
Procter & Gamble Co/The $81.20 USD +1.15
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 23.1x
Price/Sales 4.2x
Price/Book 3.1x
Price/Cash Flow 15.8x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.